Financials Evolus, Inc.

Equities

EOLS

US30052C1071

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-06-06 pm EDT 5-day change 1st Jan Change
12.4 USD -4.62% Intraday chart for Evolus, Inc. -1.67% +17.76%

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 406.8 113.4 361.8 422.4 608.2 776.4 - -
Enterprise Value (EV) 1 406.8 113.4 361.8 442.9 608.2 812.4 822.4 730.4
P/E ratio -3.82 x -0.7 x -6.93 x -5.65 x -9.75 x -17.9 x -60.5 x 14.4 x
Yield - - - - - - - -
Capitalization / Revenue 11.6 x 2.01 x 3.63 x 2.84 x 3.01 x 2.96 x 2.23 x 1.7 x
EV / Revenue 11.6 x 2.01 x 3.63 x 2.98 x 3.01 x 3.1 x 2.36 x 1.6 x
EV / EBITDA -4.29 x -2.1 x -8.45 x -10.3 x -26 x -73.8 x 16.8 x 5.85 x
EV / FCF -4.34 x - - -5.12 x - -33.8 x 49.8 x 7.42 x
FCF Yield -23% - - -19.5% - -2.95% 2.01% 13.5%
Price to Book - - - 22.8 x - - -124 x 9.54 x
Nbr of stocks (in thousands) 33,425 33,749 55,577 56,247 57,761 62,610 - -
Reference price 2 12.17 3.360 6.510 7.510 10.53 12.40 12.40 12.40
Announcement Date 2/25/20 3/24/21 3/3/22 3/8/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 34.92 56.54 99.67 148.6 202.1 262.2 347.9 455.8
EBITDA 1 -94.82 -54.04 -42.8 -43.02 -23.38 -11.01 49.05 124.9
EBIT 1 -98.95 -153.1 -44.4 -65.33 -49.23 -22.28 1.91 83.63
Operating Margin -283.31% -270.73% -44.55% -43.96% -24.36% -8.49% 0.55% 18.35%
Earnings before Tax (EBT) 1 -105.1 -162.9 -46.77 -74.32 -61.51 -39.89 -5.577 73.45
Net income 1 -90.03 -163 -46.81 -74.41 -61.68 -44.51 -13.3 52.98
Net margin -257.79% -288.31% -46.96% -50.07% -30.52% -16.97% -3.82% 11.62%
EPS 2 -3.190 -4.830 -0.9400 -1.330 -1.080 -0.6917 -0.2050 0.8620
Free Cash Flow 1 -93.73 - - -86.53 - -24 16.5 98.45
FCF margin -268.37% - - -58.22% - -9.15% 4.74% 21.6%
FCF Conversion (EBITDA) - - - - - - 33.64% 78.83%
FCF Conversion (Net income) - - - - - - - 185.82%
Dividend per Share - - - - - - - -
Announcement Date 2/25/20 3/24/21 3/3/22 3/8/23 3/7/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 34.66 33.91 37.16 33.9 43.65 41.72 49.35 50.02 61 59.33 65.2 62.36 76.18
EBITDA 1 -11.31 -14.53 -14.1 -13.28 -5.389 -5.896 -8.018 -5.731 -3.74 -0.856 1.92 -4.344 4.26
EBIT 1 -18.04 -15.45 -21.35 -17.9 -10.64 -12.04 -15.12 -13.44 -8.635 -8.922 -5.556 -5.362 -0.084
Operating Margin -52.05% -45.56% -57.44% -52.8% -24.37% -28.86% -30.64% -26.87% -14.16% -15.04% -8.52% -8.6% -0.11%
Earnings before Tax (EBT) 1 -18.18 -17.5 -23.44 -20.26 -13.11 -14.77 -18.12 -16.9 -11.72 -13.06 -9.646 -9.448 -4.168
Net income 1 -18.18 -17.4 -23.47 -20.28 -13.16 -14.79 -18.14 -16.92 -11.83 -13.11 -10.33 -10.9 -6.012
Net margin -52.45% -51.31% -63.16% -59.81% -30.16% -35.45% -36.76% -33.83% -19.4% -22.09% -15.84% -17.48% -7.89%
EPS 2 -0.3300 -0.3100 -0.4200 -0.3600 -0.2300 -0.2600 -0.3200 -0.3000 -0.2000 -0.2200 -0.1667 -0.1767 -0.0767
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/3/22 5/10/22 8/2/22 11/8/22 3/8/23 5/9/23 8/2/23 11/7/23 3/7/24 5/7/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 20.5 - 36 46 -
Net Cash position 1 - - - - - - - 46
Leverage (Debt/EBITDA) - - - -0.4765 x - -3.27 x 0.9378 x -
Free Cash Flow 1 -93.7 - - -86.5 - -24 16.5 98.5
ROE (net income / shareholders' equity) - - - -148% - - - 113%
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share 2 - - - 0.3300 - - -0.1000 1.300
Cash Flow per Share 2 - - - -1.510 - -0.3300 0.1100 1.990
Capex 1 0.35 0.82 0.39 1.62 - 6 6.5 8
Capex / Sales 0.99% 1.44% 0.39% 1.09% - 2.29% 1.87% 1.76%
Announcement Date 2/25/20 3/24/21 3/3/22 3/8/23 3/7/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
12.4 USD
Average target price
22.29 USD
Spread / Average Target
+79.72%
Consensus
  1. Stock Market
  2. Equities
  3. EOLS Stock
  4. Financials Evolus, Inc.